ERBB2 and breast carcinoma: Considering that the endocytic trafficking network has been implicated in the regulation of EGFR signaling and that CMTM6 has been explored as a therapeutic target against several malignancies including PD‐L1‐positive melanoma and HER2‐positive breast cancer,[14, 15, 23] we next investigated whether and how CMTM6 influences the EGFR signaling in NSCLC.